Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
Blood Transfusion01:15

Blood Transfusion

Blood transfusion is a critical medical procedure that saves lives and treats various medical conditions. It involves transferring blood from a donor to a recipient. This process requires a thorough understanding of the ABO blood group system and its associated antigens and antibodies.
Blood Transfusion Overview
A blood transfusion is a medical procedure used to replace blood lost due to injury, surgery, or to treat conditions such as anemia or cancer. During a transfusion, donor blood is...
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carboplatin, gemcitabine, and mifepristone for advanced breast and recurrent/persistent epithelial ovarian cancer.

Breast cancer research and treatment·2025
Same author

Brief Report: Discordance Between Liquid and Tissue Biopsy-Based Next-Generation Sequencing in Lung Adenocarcinoma at Disease Progression.

Clinical lung cancer·2023
Same author

Serving on the FDA oncologic drugs advisory committee.

Clinical advances in hematology & oncology : H&O·2022
Same author

CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer.

Scientific reports·2021
Same author

A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2021
Same author

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.

Breast cancer research and treatment·2020
Same journal

Nze C, Flowers CR. Barriers to accessing cellular therapy for patients receiving care in community practices. Hematology Am Soc Hematol Educ Program. 2023;2023(1):382-385.

Hematology. American Society of Hematology. Education Program·2025
Same journal

CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Emerging immunotherapy advances for non-Hodgkin lymphomas: engaging T cells in the fight.

Hematology. American Society of Hematology. Education Program·2025
Same journal

Anticoagulants in hematologic malignancies: what is the data?

Hematology. American Society of Hematology. Education Program·2025
Same journal

Diagnosis and management of cold agglutinin disease.

Hematology. American Society of Hematology. Education Program·2025
Same journal

What to know about rare B-cell malignancies in 2025.

Hematology. American Society of Hematology. Education Program·2025
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Immune hemolytic anemia--selected topics.

Philip C Hoffman1

  • 1University of Chicago, Chicago, IL 60637, USA. phoffman@medicine.bsd.uchicago.edu

Hematology. American Society of Hematology. Education Program
|December 17, 2009
PubMed
Summary
This summary is machine-generated.

Autoimmune hemolytic anemia (AIHA) can arise from treatments for blood cancers and transplants. Newer therapies like rituximab offer effective options for difficult AIHA cases.

Related Experiment Videos

Last Updated: Jun 17, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Area of Science:

  • Hematology
  • Immunology
  • Transplantation

Background:

  • Autoimmune hemolytic anemia (AIHA) is often idiopathic but increasingly recognized secondary to purine nucleoside analogues, blood transfusions, and ABO-mismatched transplants.
  • Immune hemolysis post-transplant, caused by donor passenger lymphocytes, can be severe. Similar syndromes occur in ABO-incompatible solid organ transplant recipients.
  • Venous thromboembolism is a recognized complication of AIHA, potentially linked to antiphospholipid antibodies. AIHA can also paradoxically arise from lymphoproliferative disorders.

Purpose of the Study:

  • To review the evolving understanding of autoimmune hemolytic anemia (AIHA).
  • To discuss associated conditions and complications of AIHA.
  • To highlight newer treatment modalities for refractory AIHA.

Main Methods:

  • Literature review of recent studies and clinical observations regarding AIHA.
  • Analysis of AIHA incidence in specific patient populations (hematologic malignancies, transplant recipients).
  • Evaluation of treatment outcomes for refractory AIHA, including novel immunosuppressives and monoclonal antibodies.

Main Results:

  • AIHA is increasingly associated with specific medical interventions and conditions.
  • Complications such as venous thromboembolism and paradoxical lymphoproliferative disorders are noted.
  • Newer treatments, including mycophenolate mofetil and rituximab, show promise for difficult AIHA cases.

Conclusions:

  • AIHA has diverse etiologies beyond idiopathic cases, including iatrogenic causes.
  • Management of AIHA requires consideration of associated risks and tailored therapeutic approaches.
  • Monoclonal antibody therapy, particularly rituximab, represents a significant advancement in treating refractory AIHA.